Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease

被引:25
作者
Foley, R [1 ]
Hollywood, D [1 ]
Lawler, M [1 ]
机构
[1] St James Hosp, Inst Mol Med, Dept Haematol & Oncol, Dublin 8, Ireland
关键词
D O I
10.1677/erc.1.00699
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microarray technology has recently accelerated the study of the molecular events involved in prostate cancer, offering the prospect of more precise prognosis and new therapeutic strategies. This review summarises current knowledge of the molecular pathology of prostate cancer. The expression and function of numerous genes have been shown to be altered in prostate cancer. Many of these genes are involved in cell cycle regulation, steroid hormone metabolism or regulation of gene expression. The mechanisms by which androgen independence arises are discussed, including cross-activation, gene amplification and point mutations of the androgen receptor. Analysis of changes in the levels of expression of large numbers of genes during prostate cancer progression have provided a better understanding of the basis of the disease, yielding new molecular markers, such as hepsin, with potential use in diagnosis and prognosis.
引用
收藏
页码:477 / 488
页数:12
相关论文
共 88 条
  • [1] ANWAR K, 1992, CANCER RES, V52, P5991
  • [2] Bakin RE, 2003, CANCER RES, V63, P1981
  • [3] Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy:: prognostic significance of p21/WAF1/CIP1 expression
    Baretton, GB
    Klenk, U
    Diebold, J
    Schmeller, N
    Löhrs, U
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) : 546 - 555
  • [4] BECKETT ML, 1991, CANCER RES, V51, P1326
  • [5] CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
    Bratt, O
    Borg, Å
    Kristoffersson, U
    Lundgren, R
    Zhang, QX
    Olsson, H
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (04) : 672 - 676
  • [6] Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays
    Bubendorf, L
    Kolmer, M
    Kononen, J
    Koivisto, P
    Mousses, S
    Chen, YD
    Mahlamäki, E
    Schraml, P
    Moch, H
    Willi, N
    Elkahloun, AG
    Pretlow, TG
    Gasser, TC
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) : 1758 - 1764
  • [7] Bubendorf L, 1999, CANCER RES, V59, P803
  • [8] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [9] Cairns P, 1997, CANCER RES, V57, P4997
  • [10] CARTER BS, 1990, CANCER RES, V50, P6830